M e d i c i n e A v e 2 1 introducing GARDASIL— helping you protect a ► GARDASIL is a vaccine indicated in girls and women 9 to 26 years of age for the prevention of cervical cancer, precancerous or dysplastic lesions, and genital warts caused by human papillomavirus (HPV) Types 6, 11, 16, and 18. ► A complete vaccination regimen of GARDASIL consists of a 3-dose schedule. Select safety information GARDASIL is contraindicated in individuals who are hypersensitive to the active substances or to any of the excipients of the vaccine. GARDASIL does not substitute for routine cervical cancer screening, and women who receive GARDASIL should continue to undergo screening per standard of care. Vaccination with GARDASIL may not result in protection in all vaccine recipients. GARDASIL is not intended to be used for treatment of active genital warts; cervical cancer; cervical intraepithelial neoplasia, vulvar intraepithelial neoplasia, or vaginal intraepithelial neoplasia. generation of girls and young women The only quadrivalent vaccine that prevents disease caused by significant human papillomavirus (HPV) types: 6,11,16, and 18 ►CERVICAL CANCER ►CERVICAL DYSPLASIA ►GENITAL WARTS ►Now is the time to vaccinate girls and young women 9 to 26 years of age. The vaccine-related adverse experiences that were observed among recipients of GARDASIL at a frequency of at least 1.0% and greater than placebo were pain, swelling, erythema, fever, nausea, pruritus, and dizziness. Please see Brief Summary of Prescribing Information on adjacent page. GARDASIL. [Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine] A new era in vaccination is here CERVICAL CANCER CERVICAL DYSPLASIA GENITAL WARTS 214
RkJQdWJsaXNoZXIy NDMwNDAx